Free Trial
NASDAQ:UPB

Upstream Bio Q1 2025 Earnings Report

Upstream Bio logo
$15.54 +0.23 (+1.50%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$15.54 0.00 (-0.03%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Upstream Bio EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Upstream Bio Revenue Results

Actual Revenue
$0.57 million
Expected Revenue
$0.71 million
Beat/Miss
Missed by -$140.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Upstream Bio's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Upstream Bio Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Upstream Bio begins phase 2 COPD trial for verekitug
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB), a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

View Upstream Bio Profile

More Earnings Resources from MarketBeat